ImmunityBio (IBRX) Stock: Climbs as FDA Expands ANKTIVA Approval for Bladder Cancer

TLDR IBRX climbs 1.12% to $9.91 as FDA expands ANKTIVA’s bladder cancer approval. FDA clears ANKTIVA plus BCG for papillary-only bladder cancer patients in the U.S. ANKTIVA’s wider label opens treatment to more patients with BCG-resistant tumors. Clinical trial finds 62% complete response rate among 77 bladder cancer patients. ImmunityBio sees a larger U.S. market [...]

The post ImmunityBio (IBRX) Stock: Climbs as FDA Expands ANKTIVA Approval for Bladder Cancer appeared first on Blockonomi.